OBJECTIVES: To evaluate the clinical PK/PD of PTH(1-34) delivered by a novel transdermal drug-coated microneedle patch system (ZP-PTH) for the treatment of osteoporosis. METHODS: Phase 1 PK studies evaluated the effect of site of administration, patch wear time and dose in normal volunteers, ages 40-85 yrs. Phase 2 was conducted in post-menopausal women with osteoporosis to determine the patch dose response compared to placebo patch and FORTEO® injection. RESULTS: Phase 1 ZP-PTH patch delivery demonstrated a rapid PTH plasma pulse profile with T(max) 3 times shorter and apparent T(1/2) 2 times shorter than FORTEO®. In Phase 2, ZP-PTH 20, 30 and 40 µg doses showed a proportional increase in plasma PTH AUC. Inter-subject and intra-subject AUC variability was similar for all patch doses and comparable to injection. All patch doses produced a significant increase in spine bone mineral density. Unexpectedly, ZP-PTH also produced an early increase in hip bone mineral density, an effect not observed with the injection. CONCLUSIONS: These studies suggest that this novel ZP-PTH patch system can deliver a consistent and therapeutically relevant PTH PK profile. Based on encouraging Phase 2 safety and efficacy data, the program is advancing into a pivotal Phase 3 clinical study.
RCT Entities:
OBJECTIVES: To evaluate the clinical PK/PD of PTH(1-34) delivered by a novel transdermal drug-coated microneedle patch system (ZP-PTH) for the treatment of osteoporosis. METHODS: Phase 1 PK studies evaluated the effect of site of administration, patch wear time and dose in normal volunteers, ages 40-85 yrs. Phase 2 was conducted in post-menopausal women with osteoporosis to determine the patch dose response compared to placebo patch and FORTEO® injection. RESULTS: Phase 1 ZP-PTH patch delivery demonstrated a rapid PTH plasma pulse profile with T(max) 3 times shorter and apparent T(1/2) 2 times shorter than FORTEO®. In Phase 2, ZP-PTH 20, 30 and 40 µg doses showed a proportional increase in plasma PTH AUC. Inter-subject and intra-subject AUC variability was similar for all patch doses and comparable to injection. All patch doses produced a significant increase in spine bone mineral density. Unexpectedly, ZP-PTH also produced an early increase in hip bone mineral density, an effect not observed with the injection. CONCLUSIONS: These studies suggest that this novel ZP-PTH patch system can deliver a consistent and therapeutically relevant PTH PK profile. Based on encouraging Phase 2 safety and efficacy data, the program is advancing into a pivotal Phase 3 clinical study.
Authors: Michel Cormier; Bonny Johnson; Mahmoud Ameri; Kofi Nyam; Luz Libiran; Dee Dee Zhang; Pete Daddona Journal: J Control Release Date: 2004-07-07 Impact factor: 9.776
Authors: L J Fraher; R Avram; P H Watson; G N Hendy; J E Henderson; K L Chong; D Goltzman; P Morley; G E Willick; J F Whitfield; A B Hodsman Journal: J Clin Endocrinol Metab Date: 1999-08 Impact factor: 5.958
Authors: Felicia Cosman; Nancy E Lane; Michael A Bolognese; Jose R Zanchetta; Pedro A Garcia-Hernandez; Karen Sees; James A Matriano; Kim Gaumer; Peter E Daddona Journal: J Clin Endocrinol Metab Date: 2009-10-26 Impact factor: 5.958
Authors: Barbara M Obermayer-Pietsch; Fernando Marin; Eugene V McCloskey; Peyman Hadji; Jordi Farrerons; Steven Boonen; Maurice Audran; Clare Barker; Athanasios D Anastasilakis; William D Fraser; Thomas Nickelsen Journal: J Bone Miner Res Date: 2008-10 Impact factor: 6.741
Authors: Hyo-Jick Choi; Dae-Goon Yoo; Brian J Bondy; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz Journal: Biomaterials Date: 2012-02-21 Impact factor: 12.479
Authors: Nadine G Rouphael; Michele Paine; Regina Mosley; Sebastien Henry; Devin V McAllister; Haripriya Kalluri; Winston Pewin; Paula M Frew; Tianwei Yu; Natalie J Thornburg; Sarah Kabbani; Lilin Lai; Elena V Vassilieva; Ioanna Skountzou; Richard W Compans; Mark J Mulligan; Mark R Prausnitz Journal: Lancet Date: 2017-06-27 Impact factor: 79.321
Authors: Megan N Kelchen; Grant O Holdren; Matthew J Farley; M Bridget Zimmerman; Janet A Fairley; Nicole K Brogden Journal: Pharm Res Date: 2014-06-20 Impact factor: 4.200